Premium
Impact of parainfluenza virus infection in pediatric cancer patients
Author(s) -
Maeng Se Hyun,
Yoo Hye Soo,
Choi SooHan,
Yoo Keon Hee,
Kim YaeJean,
Sung Ki Woong,
Lee Nam Yong,
Koo Hong Hoe
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23390
Subject(s) - medicine , respiratory infection , pneumonia , upper respiratory tract infection , cancer , lower respiratory tract infection , virus , respiratory tract , pediatric cancer , infection control , respiratory tract infections , pediatrics , respiratory system , intensive care medicine , immunology
Background Respiratory virus (RV) infection can cause significant morbidity and mortality in pediatric cancer patients. Parainfluenza virus (PIV) is a common pathogen in childhood among the respiratory viruses. The objective of this study is to evaluate the impact of parainfluenza virus infection in pediatric cancer patients. Procedure A retrospective review of medical records of 1,554 children diagnosed with cancer from January 2000 through July 2008 was analyzed at Samsung Medical Center. Results A total of 6.4% (137/1,554) had respiratory virus infection and 54% (74/137) of patients with RV infection had PIV infection. PIV type 3 was the predominant subtype. Among patients with PIV infection, 59 children (79.7%) had upper respiratory tract infection (URI) whereas 15 children (20.3%) had lower respiratory tract infection (LRI) at initial presentation. Among patients with URI, 12 (20.3%) progressed to pneumonia with the median interval of 4 days from URI to LRI. Mortality associated with PIV infection was 18.5% (5/27) in patients with LRI. Among patients with PIV infection, 80% (59/74) had nosocomial infection, which shows the difficulty and importance of infection control at pediatric cancer ward. Conclusions PIV infection was most commonly diagnosed among pediatric cancer patients with RV infection and PIV infection led to significant pulmonary complications and direct mortality in immunocompromised children. Since there are no effective antiviral agents for PIV infection, precautionary infection control and early diagnosis are the only methods available to prevent the infection spread. Pediatr Blood Cancer 2012;59:708–710. © 2012 Wiley Periodicals, Inc.